Regeneron Pharmaceuticals, Inc. (REGN)
852.29
+28.47
(+3.46%)
USD |
NASDAQ |
Sep 02, 16:00
852.29
0.00 (0.00%)
After-Hours: 17:04
Regeneron Pharmaceuticals Free Cash Flow : 3.575B for June 30, 2026
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | 3.575B |
| March 31, 2026 | 3.791B |
| December 31, 2025 | 3.765B |
| September 30, 2025 | 3.881B |
| June 30, 2025 | 3.556B |
| March 31, 2025 | 2.962B |
| December 31, 2024 | 3.539B |
| September 30, 2024 | 3.319B |
| June 30, 2024 | 3.184B |
| March 31, 2024 | 3.930B |
| December 31, 2023 | 3.668B |
| September 30, 2023 | 4.359B |
| June 30, 2023 | 3.004B |
| March 31, 2023 | 2.527B |
| December 31, 2022 | 3.398B |
| September 30, 2022 | 4.148B |
| June 30, 2022 | 7.869B |
| March 31, 2022 | 7.936B |
| December 31, 2021 | 6.529B |
| September 30, 2021 | 5.381B |
| June 30, 2021 | 1.694B |
| March 31, 2021 | 2.029B |
| December 31, 2020 | 2.004B |
| September 30, 2020 | 1.582B |
| June 30, 2020 | 2.425B |
| Date | Value |
|---|---|
| March 31, 2020 | 1.706B |
| December 31, 2019 | 2.000B |
| September 30, 2019 | 1.995B |
| June 30, 2019 | 1.906B |
| March 31, 2019 | 2.095B |
| December 31, 2018 | 1.812B |
| September 30, 2018 | 1.628B |
| June 30, 2018 | 1.636B |
| March 31, 2018 | 1.268B |
| December 31, 2017 | 1.034B |
| September 30, 2017 | 802.62M |
| June 30, 2017 | 979.92M |
| March 31, 2017 | 1.326B |
| December 31, 2016 | 961.46M |
| September 30, 2016 | 838.08M |
| June 30, 2016 | 1.052B |
| March 31, 2016 | 795.41M |
| December 31, 2015 | 652.85M |
| September 30, 2015 | 629.54M |
| June 30, 2015 | -33.42M |
| March 31, 2015 | 219.78M |
| December 31, 2014 | 410.15M |
| September 30, 2014 | 537.22M |
| June 30, 2014 | 514.19M |
| March 31, 2014 | 350.98M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Alnylam Pharmaceuticals, Inc. | 793.94M |
| AbbVie, Inc. | 18.21B |
| Gilead Sciences, Inc. | 12.94B |
| Amgen, Inc. | 10.18B |
| Biogen, Inc. | 2.49B |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | 813.00M |
| Cash from Investing (Quarterly) | -92.70M |
| Cash from Financing (Quarterly) | -1.225B |
| Free Cash Flow Per Share (Quarterly) | 4.923 |
| Free Cash Flow to Equity (Quarterly) | 521.40M |
| Free Cash Flow to Firm (Quarterly) | 531.14M |
| Free Cash Flow Yield | 3.92% |